Clinical profile of comorbidity of rare diseases in a Tunisian patient: a case report associating incontinentia pigmenti and Noonan syndrome

Nehla Ghedira 1,2*, Arnaud Lagarde 2,4, Karim Ben Ameur 3,1, Sahar Elouej 2,6, Rania Sakka 1,3, Emna Kerkeni 1, Fatma-Zohra Chioukh 1,1, Sylviane Olschwang 2,4,5, Jean-Pierre Desvignes 2, Sonia Abdelhak 6, Valerie Delague 2, Nicolas Lévy 2,4, Kamel Monastiri 3,1 and Annachiara De Sandre-Giovannoli 2,4

Abstract

Background: Noonan syndrome (NS) is an autosomal dominant multisystem disorder caused by the dysregulation of several genes belonging to the RAS Mitogen Activated Protein Kinase (MAPK) signaling pathway. Incontinentia Pigmenti (IP) is an X-linked, dominantly inherited multisystem disorder.

Case presentation: This study is the first report of the coexistence of Noonan (NS) and Incontinentia Pigmenti (IP) syndromes in the same patient. We report on the clinical phenotype and molecular characterization of this patient. The patient was examined by a pluridisciplinary staff of clinicians and geneticist. The clinical diagnosis of NS and IP was confirmed by molecular investigations. The newborn girl came to our clinics due to flagrant dysmorphia and dermatological manifestations. The clinical observations led to characterize the Incontinentia Pigmenti traits and a suspicion of a Noonan syndrome association. Molecular diagnosis was performed by Haloplex resequencing of 29 genes associated with RASopathies and confirmed the NS diagnosis. The common recurrent intragenic deletion mutation in IKBKG gene causing the IP was detected with an improved PCR protocol.

Conclusion: This is the first report in the literature of comorbidity of NS and IP, two rare multisystem syndromes.

Keywords: Noonan syndrome, RAS-MAPK pathway, RAF1, Dysmorphism, Incontinentia Pigmenti, X-linked disorder, Comorbidity, Next generation sequencing

Background

Noonan syndrome (NS, OMIM 163950) is one of the most frequent genetic disorders in children with an autosomal dominant pattern of inheritance [1, 2]. This multisystem disease is variably expressed with an estimated prevalence of 1 in 1000–2500 live births [1, 3].

The clinical diagnosis of NS is established on the basis of distinctive features according to different criteria developed by Van Der Burgt and al [4] in 1994. Constant clinical traits characterizing this syndrome include: dysmorphic facial features, variable developmental delay with constant short stature, congenital heart defects and chest wall anomaly often consisting of pectus carinatum or/and pectus excavatum [5–7]. NS has also a distinct constellation of ectodermal manifestations that depends on the mutated gene including short and curly hair, loose anagen hair, absent eye-brows, erthema, and granular cell tumors, abnormal pigmented lesions (multiple pigmented naevi, “café au lait” spots and freckles. Keratosis pilaris can also occurs [8–11].

NS has a heterogeneous genetic background that involves genes encoding proteins with roles in the RAS MAPK pathway [5, 12–14]. Gain of function mutations in the PTPN11 gene (OMIM 176876) are found in 40–50% of NS patients [10, 15, 16]. Other mutations in
several genes of the cascade are less frequent: e.g. in SOS1 (OMIM 182530, about 11% of cases), RAF1 (OMIM 164760, about 5% of cases), SHOC2 (OMIM 602775, about 2% of cases), KRAS (OMIM 190070, about 1.5% of cases), NRAS (OMIM 164790, about 0.2% of cases), CBL (OMIM 165360), RIT1 (OMIM 609591) and recently, with the emergence of NGS technologies in the molecular characterization of rare diseases, other genes have been implicated such as RRAS (OMIM 165090), RASA2 (OMIM 601589), SOS2 (OMIM 601247) and LZTR1 (OMIM 600774) [5, 17–19]. Nevertheless, about 30% of NS cases remain without molecular confirmation.

Familial Incontinentia Pigmenti (IP, OMIM 308300) is a rare X-linked dominant genodermatosis that affects ectodermal tissues and is usually perinatally lethal in males [20, 21]. However, some affected males have been reported, either presenting with X-chromosome somatic mosaicism or a concomitant diagnosis of Klinefelter syndrome [22]. In total, 900 to 1200 individuals with IP have been reported in the literature.

More than 80% of IP patients have a recurrent genomic large-scale deletion of exons 4–10 of the NEMO gene (IKBKG, OMIM 300248), which encodes a regulatory component of the IKB Kinase complex, leading to loss of NF-KB activation and increased apoptosis. Although hypomorphic mutations and CNVs have been reported, the architecture of the NEMO/IKBKG locus seems to facilitate genome instability generating the high frequency of de novo rearrangements observed in IP patients [20, 23, 24].

Case presentation
The patient was a one-month-old baby girl referred to our center for a congenital heart defect. The baby was born at full term (40-week s gestation). Pregnancy, as well as the perinatal period, were unremarkable. The baby had facial dysmorphism with broad forehead, hypertelorism, down-sloping palpebral fissures, a high arched palate, bifid uvula and low set posteriorly rotated ears, long philtrum and epicanthal folds (Fig. 1a, b). Echocardiography showed pulmonic stenosis. During the first week of life, the baby developed Incontinentia Pigmenti, a typical skin rush that started with papules, vesicles and pustules on an erythematous base, followed by plaques and warty papules linearly arranged over erythematous lesions, then a linear brownish pigmentation plaques and warty papules linearly arranged over eczema and pustules on an erythematous base, followed by erythematous plaques. The baby had congenital stridor, delayed neurological development and growth retardation (weight was 4000 g at 2 months, < P3). These findings were consistent with Noonan syndrome associated with Incontinentia Pigmenti based on “Incontinentia Pigmenti diagnostic criteria update” by Minicand al [25]. The phenotypes of the two syndromes evolved with the age of the patient (Fig. 1g-j).

Methods
The clinical data were compiled by clinical geneticists and pediatricians (R. S, K.BA, K.M, and FZ.C). The patient’s parents signed written informed consent to consultation and molecular studies for both diagnostic and research purposes and also for publication of the patient’s pictures. Along this, parents give also their consent for participation in genetic testing in addition to their child. This work complies with the declaration of Helsinki (https://www.wma.org/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/) and with the ethical guidelines of the institutions involved. Genomic DNA of the patient and her parents was manually extracted from peripheral blood collected in EDTA tubes according to standard salting out methods and purified by QiAmp CDN kit (Qiagen). DNA quality and quantity were measured on Nanodrop Spectrophotometer (Thermo Scientific) and by Qubit ds S Assay on Qubit 2.0 Fluorometer (Thermo Fisher Scientific).

NGS analysis
A panel of 29 genes was designed using the online Sure Design software (Agilent Technologies). A predesigned Haloplex Noonan panel containing the genes PTPN11, SOS1, RAF1, KRAS, BRAF, NRAS, HRAS, MAP2K1, MAP2K2, SHOC2, CBL, SPRED1 and NFI was used, to which were added other genes involved in RASopathies (the list of all analyzed genes can be provided on request). The size of the final target region was 232.387kpb with 570 amplicons and the mean sequence coverage was 93.73 at 20× prior 99.41% coverage of the target region. The preparation of the libraries was performed using the Haloplex target enrichment system dedicated to Ion Torrent PGM. Massively parallel sequencing was performed on an Ion Torrent PGM (Thermo Fisher Scientific).

Raw data generated by the PGM sequencer were processed by Torrent Suite Software v.4 and aligned using TMAPv.3. Sequence variants were identified using the Variant Caller tool from the Ion Torrent package using default “germline low stringency” parameters (min_coverage: 6 snp and indel; strand_bias: 0.98 snp and 0.85 indel) then prioritized using the in-house software Varaft (http://varaft.eu) that includes Annovar [26] and UMP-Predictor [27]. Variants not previously reported in healthy controls and classified as pathogenic were evaluated for sequencing depth and
visually inspected using the Integrative Genomic Viewer (IGV) before validation by Sanger Sequencing using the manufacturer’s protocol for BigDye® Terminator sequencing kits. Segregation analysis was performed in both parents by Sanger sequencing.

Genes were named following the Hugo gene nomenclature committee guidelines (https://www.genenames.org/); DNA mutations and predicted protein changes were named following the HGVS nomenclature guidelines available at http://www.hgvs.org/mutnomen/. The NS-Euronet mutation database was used to check for mutation description at https://nseuronet.com/php/.

**PCR amplification method**

We used an improved PCR protocol amplification which provides a robust detection of the recurrent intragenic deletion that removes exon4–10. This protocol has been previously described by Guevara et al. [28].

---

**Fig. 1** Photographs of the patient showing NS and IP manifestations. **a, b** front and profile photo respectively pointing facial dysmophism at the age of 1 month with broad forehead, hypertelorism, down-slanting palpebral fissures, a high arched palate, bifid uvula and low set posteriorly rotated ears, long philtrum and epicanthal folds; **c-f** typical IP manifestations at the age of 1 month showing linear brownish pigmentation involving the trunk and the extremities; **g, h** front and profile photo of the patient at the age of 1 year highlights the evolution of NS phenotype; **i, j** evolution of the IP manifestations at the age of 1 year, pectus excavatum becomes more pronounced.
Results
A total of 184 variants were detected across the 29 genes analyzed. Filtering these results using in silico software predictors of a mutation’s impact such as UMD predictor, Mutation-taster, PolyPhen and others, whose algorithms are integrated into the Varaf software, issued only one heterozygous variant as potentially pathogenic: a heterozygous SNV in exon 7 of the \textit{RAF1} gene predicted to lead to a missense amino acid change (NM_002880: c.788 T > G, p. Val263Gly) (Fig. 2a). This was retained since it was correlated to the phenotypic description of the patient and was already reported \cite{29}. We confirmed this alteration in the patient by Sanger Sequencing. The analysis of transmission in the patients’ parents confirmed that it occurred as de novo mutation (Fig. 2b).

Presence of a de novo exon 4–10 deletion of \textit{IKBKG} gene was demonstrated by PCR amplification in the proband (Fig. 3a) and was confirmed in the proband’s DNA using Sanger Sequencing of the 1045-bp band confirming a breakpoint in intron 3 (Fig. 3b).

Discussion and conclusion
To the best of our knowledge, this is the first reported clinical case of NS associated with IP in a non-consanguineous female patient. As previously discussed, several causal genes
are associated with the NS phenotype, including PTPN11, SOS1, RAF1, BRAF, NRAS, SHOC2, CBL, and RIT1.

Our patient harbored a mutation in RAF1, in which rare substitutions were previously reported in the context of NS and RASopathies [30–32]. RAF1 (OMIM, 164760) is a mitogen activated protein kinase kinase that constitutes, in addition to BRAF and ARAF, a small family of serine threonine kinases which relays signals from activated RAS proteins to the major effectors of this pathway, ERK1/2 via MEK1/2. Compared to BRAF, RAF1 and ARAF have considerably lower MEK kinase activity, different expression profiles and also distinct regulatory mechanisms: missense mutations in these two genes are thus rarely observed in malignancies [10]. The ubiquitously expressed RAF1 encodes a 648 amino acids protein containing three functional and conserved domains: the N-terminal CR1 (amino acids residues 61–192), CR2 (residues 251–266),, and CR3 kinase domain (residues 333–625) [33].

About 70% of all the RAF1 mutations identified to date are amino acid substitutions located in the CR2 domain. The second group of mutations, identified in 15% of NS or LS-causing RAF1 mutations, affects the kinase domain and the last 15% of RAF1 mutations affects two adjacent residues, located at the C-terminus. None of the mutations causing NS or LS are reported in a cancer context.

Our patient’s mutation is localized at position Val263, adjacent to the most frequently mutated residues, in the same CR2 domain. Functional characterizations support that mutations which affect the 14–3-3 binding motif (such is in our case) cause an enhanced kinase activity in downstream RAS signaling (MEK and ERK) [10, 29, 34]. The exact mechanism of RAF1 activation in mutants remains unexplained.

Our patient showed a mutation that was previously described prenatally in a fetus showing evocative signs of Noonan syndrome (fetal hydrops and cystic hygroma-coll) together with hypoplastic left heart syndrome (HLHS), one of the most severe congenital heart defects, characterized by underdevelopment of the structures in the left-aorta complex and detectable by ultrasound at prenatal sonography between 18 and 22 weeks of gestation of the fetal heart. In Noonan syndrome patients, HLHS has only been described twice [35]. The same mutation caused in our patient one of the two most frequent congenital heart defects observed in NS: pulmonic stenosis, suggesting that other factors (genetic or environmental) are involved in the determination of the cardiac anomaly, in addition to the RAF1 p.Val263Gly mutation.

Gain of function mutations in RAF1 were identified for the first time in 2007 in patients with NS and negative for PTPN11, KRAS and SOS1 mutations and two of six patients with LEOPARD syndrome [31, 36], with a
frequency ranging between 10 and 30%. Examination of
detailed clinical manifestations of these patients showed
a strong association among \( \text{RAF1} \) mutations and con-
genital cardiac defects (94% of children carrying \( \text{RAF1} \)
gene mutation), namely hypertrophic cardiomyopathy
(HCM) in 70–80% of the patients, which is significant
compared to the 18% HCM prevalence observed in the
general NS population [10], but atrial septal defects
compared to the 18% HCM prevalence observed in the
(12%), pulmonary valve stenosis (12%), and arrhythmia
are also observed [37].

Craniofacial characteristics, skeletal abnormalities and
mental retardation can also be present. Skin and hair
anomaly are less marked, but multiple \( \text{naevi} \), caféd-au-lait
spots and lentigines were present in one-third of NS pa-
tients with \( \text{RAF1} \) mutations, that suggests a predispos-
tion to hyperpigmented cutaneous lesions [10, 34, 38–
40]. In IP affected females, major linear skin hyperpig-
mentation can be associated with a variety of ophthalmic
disorders (strabismus, retinopathy, congenital cata-
ract...), nail and teeth dysplasia and occasionally central
nervous system disease ranging from seizures to severe
motor and intellectual delay [21]. Differently to NS,
skin lesions of IP occur in 4 classic cutaneous stages,
observed in our patient: stage 1 is characterized by
erythema, vesicles, and pustules; stage 2 by papules,
verrucous lesions, and hyperkeratosis; stage 3 by
hyperpigmentation; and stage 4 by pallor, atrophy,
and scarring [41]. Nail dystrophy is frequent but usu-
ally mild [25].

The relatively low incidence of \( \text{RAF1} \) gene mutations
in patients with NS and the much rarer onset of cutane-
ous disorders within this category of patients make it
difficult to establish a clear genotype/phenotype correl-
ation and to better explain the possible underlying
mechanism of such a rare association of NS phenotypes.
The association between NS due to a \( \text{RAF1} \) mutation
and another disease in one patient has been rarely re-
ported. Cerebrovascular anomalies [42], Burkitt lymph-
oma [43] and usually cardiomyopathies [34, 44] have
been associated to NS.

Conclusion
The Co-occurrence of two or several diseases has been re-
cently reported in Tunisian population. This phenomenon
has been observed mainly for autosomal recessive diseases
and is due to the high rate of consanguinity [45, 46].
Nevertheless, the association we report between NS
and IP is probably coincidental since no link has been
established among the 2 pathophysiological pathways
and high rates of consanguinity in the Tunisian pa-
tients’ population are not likely to influence the
appearance of IP nor NS, whose inheritance patterns
are not autosomal recessive.

Abbreviations
CNV : Copy Number variation; HCM: Hypertrophic Cardiomyopathy;
HLHS: Hypoplastic Left Heart Syndrome; IP : Incontinentia Pigmenti;
NS: Noonan Syndrome; PCR : Polymeras Chain Reaction; RAS MAPK: Ras
Mitogen Activated Protein Kinase

Acknowledgments
We thank the patient and her family for participating in this research. We
would like to thank also both the personnel of the Department of intensive
care and neonatal medicine, CHU Fattouma Bourguiba, Monastir, Tunisia
and all members of the team of the INSERM Unit UMR 5910, GMGF, Aix Marseille
University, Marseille, France (Karim Harhouri, Cathy Bartoli, Guy Longepied,
Françoise Merono). We also thank Pr Moncef Rassas for his helpful comments.

Funding
This study was partially funded by the University Foundation A*MIDEX by
providing the Haloplex kit and the reagents needed for this study.

Availability of data and materials
The datasets used and/or analyzed during the current study available from
the corresponding author on reasonable request.

Authors’ contributions
NG, AL, SE and EK carried out experimental work and result interpretation.

Clinical details and evaluation were carried out by KBA, MK and RS. NL, ADG,
SO and VD supervised research work. JPD has refined the software used in
this work.NL had contributed to the discussion and scientific evaluation
of this work and approved all results. NG, ADG, FZC and SA refined the
manuscript for publication. SO and VD have provided technical resources
essential for the realization of this work. All authors read and approved the
final manuscript for publication.

Ethics approval and consent to participate
The study was performed on the basis of diagnostic testing and that informed
consents were obtained from the parents of the minor patient included in this
work during a medical genetics consultation. Ethics committee approval was
obtained from the teaching hospital of Monastir in Tunisia. The patient’s
parents signed written informed consent to consultation and molecular studies
for both diagnostic and research purposes and also for publication of the
patient’s pictures. Along this, parents give also their consent for participation in
 genetic testing in addition to their child.

Consent for publication
Written informed consent for case reporting and picture publication was
obtained from patient’s parents in accordance with the Declaration of
Helsinki.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.

Author details
1 Research Unit 01/UR/08-14, Faculty of Medicine of Monastir, University of
Monastir, Avenue Avicenne, 5019 Monastir, Tunisia. 2 Aix Marseille University,
INSMER, GMGF, Marseille, France. 3 Department of Intensive Care and
Neonatal Medicine, Fattouma Bourguiba University Hospital, Monastir,
Tunisia. 4 Department of Medical Genetics, Children’s Hospital La Timone,
264 Rue Saint Pierre, Marseille, France. 5 Groupe Ramsay Générale de Santé,
Hôpital Clairval, Marseille, France. 6 Institut Pasteur de Tunis, Laboratoire de
Genomique Biomédicale et Oncogénétique LR11FT05, Tunis, Tunisia.

Received: 14 June 2017 Accepted: 20 August 2018
Published online: 29 August 2018

References
1. Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet.
2013;381:313–42.
2. Turner AM. Noonan syndrome. J Paediatr Child Health. 2014;50:E14–E20.

Ghedira et al. BMC Pediatrics (2018) 18:286
3. Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, et al. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics. 2010;126:746–59.

4. Van der Burgt I, Berends E, Lommen E, Van Beersum S, Hamel B, Mariman E. Clinical and molecular studies in a large Dutch family with Noonan syndrome. Am J Med Genet. 1994;53:187–91.

5. Zenker M. Genetic and pathogenetic aspects of Noonan syndrome and related disorders. Horm Res. 2009;72:57–63.

6. Allanson JE, Bohring A, Dör H-G, Dufke A, Gillessen-Kaesaeth G, Horn D, et al. The face of Noonan syndrome: does phenotype predict genotype. Am J Med Genet A. 2010;152A:1960–6.

7. Bhamidhavi N, Muenke M. Noonan syndrome. Am Fam Physician. 2014;89:37–43.

8. AAL J, Malagias AC, IJP A, Mendonca BB. Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS/MAPK pathway. Horm Res. 2009;71:185–93.

9. Narumi Y, Aoki Y, Niihori T, Sakurai M, Cava H, Verloes A, et al. Clinical manifestations in patients with SOS1 mutations range from Noonan syndrome to CFC syndrome. J Hum Genet. 2008;53:38–41.

10. Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol. 2010;1:2–26.

11. Nishihara S, Hatae K, Umezawa H, Hiyazumi A, Mucumbuti J, Riusingiza EK, et al. Patients with Noonan Syndrome phenotype: spectrum of clinical features and congenital heart defect. Rwanda Medical Journal 2010;62:31–2006;15:R220–6.

12. TumorHsu M, Saltos M, Sato A, Takahashi K, Mima M, Takita J, et al. Comprehensive genetic analysis of overlapping syndromes of RAS/RAF/MEK/ERK pathway. Pediatr Int. 2010;52:557–62.

13. Gelb BD, Tartaglia M. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum Mol Genet. 2006;15:R220–6.

14. Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras/RAF/MAPK pathway dysregulation. Curr Opin Genet Dev. 2009;19:230–6.

15. Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol. 2010;1:2–26.

16. Nishihara S, Hatae K, Umezawa H, Hiyazumi A, Mucumbuti J, Riusingiza EK, et al. Patients with Noonan Syndrome phenotype: spectrum of clinical features and congenital heart defect. Rwanda Medical Journal 2010;62:31–2006;15:R220–6.

17. TumorHsu M, Saltos M, Sato A, Takahashi K, Mima M, Takita J, et al. Comprehensive genetic analysis of overlapping syndromes of RAS/RAF/MEK/ERK pathway. Pediatr Int. 2010;52:557–62.

18. Tartaglia M, Zampino G, Gelb BD. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum Mol Genet. 2006;15:R220–6.

19. Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras/RAF/MAPK pathway dysregulation. Curr Opin Genet Dev. 2009;19:230–6.

20. Tartaglia M, Zampino G, Gelb BD. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum Mol Genet. 2006;15:R220–6.

21. Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras/RAF/MAPK pathway dysregulation. Curr Opin Genet Dev. 2009;19:230–6.

22. Ormerod AD, White MI, McKay E, Johnston AW. Incontinentia pigmenti in a newborn infant with a 22q11 deletion. J Med Genet. 2007;43:680–6.

23. Fusco F, Bardaro T, Fimiani G, Mercadante V, Miano MG, Falco G, et al. Improved molecular diagnosis of the common recurrent intragenic deletion mutation in IKBKG in a Filipino family with incontinentia pigmenti. J Hum Genet. 2010;56:150–3.

24. Rauen KA, Huson SM, Burkitt-Wright E, Evans DG, Farschtschi S, Ferner RE, et al. Two cases of LEOPARD syndrome – RAF1 mutations firstly described in children. Turk J Pediatr. 2011;53:687–91.

25. Willbrock C, Karasidès M, Marais R. The RAF proteins take Centre stage. Nat Rev Mol Cell Biol. 2004;5:875–85.

26. Saito Y, Niihori T, Sakurai M, Cava H, Verloes A, Okamoto N, et al. Identification of a novel de novo deletion in RAF1 associated with biventricular hypertrophy in Noonan syndrome. Am J Med Genet Part A. 2014;164:2069–73.

27. Antenelli D, Antonelli J, Rosenfeld T. Noonan’s syndrome associated with hypoplastic left heart. Cardiovasc Pathol. 1999;10:762–5.

28. Kobayashi T, Aoki Y, Niihori T, Cava H, Verloes A, Okamoto N, et al. Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation. Hum Mutat. 2010;31:284–94.

29. Pandit B, Sarkozy A, Pennacchio LA, Pezzoli L, Preda L, Musco G, et al. Identification of a novel de novo deletion in RAF1 associated with biventricular hypertrophy in Noonan syndrome. Am J Med Genet Part A. 2014;164:2069–73.

30. Ben Abdallah L, et al. Comorbidity in the Tunisian population. Clin Genet. 2016;90:587–93.

31. Young I, Wilkie A. Syndrome of the month. J Med Genet. 1994;31:744.

32. Tartaglia M, Gelb BD. Disorders of dysregulated signal traffic through the RAS/MAPK pathway. Pediatr Int. 2010;52:557–62.

33. Wellbrock C, Karasidès M, Marais R. The RAF proteins take Centre stage. Nat Rev Mol Cell Biol. 2004;5:875–85.

34. Ben Abdallah LC, Lakhoua Y, Nagara M, Khiari K, Elouej S, Messaoud O, et al. Two cases of LEOPARD syndrome - RAF1 mutations firstly described in children. Turk J Pediatr. 2011;53:687–91.

35. Pandit B, Sarkozy A, Pennacchio LA, Pezzoli L, Preda L, Musco G, et al. Identification of a novel de novo deletion in RAF1 associated with biventricular hypertrophy in Noonan syndrome. Am J Med Genet Part A. 2014;164:2069–73.

36. Antenelli D, Antonelli J, Rosenfeld T. Noonan’s syndrome associated with hypoplastic left heart. Cardiovasc Pathol. 1999;10:762–5.

37. Pandit B, Sarkozy A, Pennacchio LA, Pezzoli L, Preda L, Musco G, et al. Identification of a novel de novo deletion in RAF1 associated with biventricular hypertrophy in Noonan syndrome. Am J Med Genet Part A. 2014;164:2069–73.

38. Antenelli D, Antonelli J, Rosenfeld T. Noonan’s syndrome associated with hypoplastic left heart. Cardiovasc Pathol. 1999;10:762–5.

39. Kobayashi T, Aoki Y, Niihori T, Cava H, Verloes A, Okamoto N, et al. Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation. Hum Mutat. 2010;31:284–94.

40. Tartaglia M, Gelb BD. Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci. 2010;1214:99–121.

41. Young I, Wilkie A. Syndrome of the month. J Med Genet. 1994;31:744.

42. Saray Mitar, Vukomanov K, Vukomanov S, Cevcic I, Nenadic D, Mijatovic C, et al. Unique cerebrovascular anomalies in Noonan syndrome with RAF1 mutations. J Med Genet A. 2013;50:319–22.

43. Cianci P, Tono V, Sala A, Locatelli L, Carta C, Rizzari C, et al. A boy with Noonan syndrome associated with a novel mutation in the RAF1 gene. J Pediatr. 2011;158:146–7.

44. Gelb BD, Roberts AE, Tartaglia M. Cardiomyopathies in Noonan syndrome and related disorders. Best Pract Res Clin Endocrinol Metab. 2011;25:161–76.

45. Ben Abdallah L, et al. Comorbidity in the Tunisian population. Clin Genet. 2016;90:587–93.

46. Romdhane L, Messaoud O, Bouyacoub Y, Kerkeni E, Naouali C, Cherif Ben Abdallah LC, et al. Comorbidity in the Tunisian population. Clin Genet. 2016;90:587–93.

47. Wang K, Li M, Hakonarson H, et al. Nucleic Acids Res. 2010;38(16):e164. https://doi.org/10.1093/nar/gkq603.